Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  5. Blackhawk Growth Corp.
  6. News
  7. Summary
    BLR   CA09238B3083


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Blackhawk Growth : SAC Pharma Continues to Expand Product Line and Services

10/12/2021 | 06:01am EST

(via TheNewswire)

Blackhawk Growth Corp.

Vancouver, British Columbia -TheNewswire -October 12, 2021 - Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company”), is excited to provide an update on the expansion of products and operations for Sac Pharma Partners USA (“SAC Pharma”), its wholly ownedsubsidiary. In an effort to further broaden its product line, Sac Pharma has secured four new exclusive cultivars on exclusive buy-back agreements from sought after geneticists. Sac Pharma will be able to charge a market premium on these strains for those who wish to bring branded products to market, but do not have the reach, infrastructure, and established distribution Sac Pharma has developed.


Sac Pharma continues to develop its proprietary intellectual property, and will be bringing its new signature strain Morado to market this month, with the initial production run of Morado being completely pre-sold.  Sac Pharma also expects to be in a position to release their next line of proprietary strains, code name A-11, to market this quarter. Development and initial testing for A-11 has been extremely promising.  The Company plans to continue to develop its research and development process, and is already engaged in long term planning for new strains to be released in the future. Continued development and distribution of proprietary strains will increase the market share that Sac Pharma products currently holds.


Sac Pharma is also expanding its management services to include canopy management and compliance to other producers and has come to terms on a compliance engagement for a large-scale Sacramento facility.  These arrangements assist Sac Pharma in growing its revenue base within its footprint, as well as providing a means to pursue revenue opportunities outside its primary facility.


“The strengthening of Sac Pharma’s business model continues” said Frederick Pels, CEO of Blackhawk Growth Corp. “The addition of canopy management with an evolving catalogue of proprietary genetics will ensure continued growth, allowing Sac Pharma to further serve its client base with in demand products.”


Debt Settlement


The Company also announces that it has entered into a debt settlement agreement with an arm’s-length creditor to settle indebtedness totaling $52,500 incurred in connection with services provided to the Company.  In final settlement and satisfaction of the debt, the Company has issued 87,500 common shares at a deemed issue price of $0.60 per share.


All shares issued in connection with the debt settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

For more information on Blackhawk, please visit our website at:



About Blackhawk Growth


Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods and MindBio Therapeutics.Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channelhttps://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group athttps://t.me/Blackhawkgrowthcorpand visit us online athttps://www.blackhawkgrowth.com.

Frederick Pels, Chief Executive Officer



Frederick Pels, Chief Executive Officer



Cautionary Note Regarding Forward-Looking Statement


All statements in this press release, other thanstatements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and Sac Pharma USA. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise anyforward-looking information, whether as a result of new information, future events or otherwise unless required by law.


Copyright (c) 2021 TheNewswire - All rights reserved.

Copyright (c) 2021 TheNewswire - All rights reserved., source Press Releases

12/01Blackhawk Growth Completes Investment in California-Based Licensed Distribution Center ..
11/29Blackhawk Growth Files Quarter Ended September 30, 2021 Financials and Reports Increase..
11/29Blackhawk Growth Corp. Reports Earnings Results for the First Quarter Ended September 3..
11/23Blackhawk Growth Corp. Announces Financing Agreement
11/23Blackhawk Growth Enters into Credit Facility for up to $10 Million
11/23Blackhawk Growth Corp. announced that it expects to receive CAD 10 million in funding
11/15Blackhawk growth's mindbio therapeutics advances microdosing clinical trial to 59 patie..
11/15Blackhawk Growth's MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patie..
11/08Blackhawk growth's mindbio therapeutics completes safety milestone in its phase 1 clini..
11/08Blackhawk Growth's MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clini..
More news
Sales 2021 0,83 M 0,65 M 0,65 M
Net income 2021 -2,52 M -1,96 M -1,96 M
Net cash 2021 0,68 M 0,53 M 0,53 M
P/E ratio 2021 -3,33x
Yield 2021 -
Capitalization 30,1 M 23,5 M 23,4 M
EV / Sales 2020 -15,0x
EV / Sales 2021 13,7x
Nbr of Employees -
Free-Float 97,8%
Duration : Period :
Blackhawk Growth Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Frederick Pels President, Chief Executive Officer & Director
David M. Antony Chairman
Dale S. Owen Independent Director
Alexander Klenman Director
Marc Lowenstein Director
Sector and Competitors
1st jan.Capi. (M$)
BLACKSTONE INC.117.93%96 654
KKR & CO. INC.81.82%43 068
LEGAL & GENERAL PLC7.40%22 436
AMUNDI5.39%16 087